… The Japanese authorities arrested seven central figures in the huge accounting scandal at Olympus — including the camera maker’s former chairman and executive vice president — on Thursday as part of investigations into a decade-long cover-up that has prompted concern over what critics say is lax corporate governance at Japanese companies. Tsuyoshi Kikukawa, a [...]
Tag Archives: acroMIS
Olympus EX-President and helpers arrested – falsifying financial statements is a crime
Friday, February 17, 2012
Filed in Ideas For Surgery News
|
Also tagged $2 billion acquisition, 2012 California Biomedical Industry Report, Accelerate Globalization, Accelerated investments, accelerated investments to serve the emerging markets, accelerating globalization, Access to capital, acquisition of technologies, acromis implementation and development, address patients’ need, address the high risk, adoption of austerity measures, advantageous position, adverse impact on technology, age-related disease, Akio Nakagawa, Altis, Altis and Humalabo, angel investors, around the globe, Asia, Attain the desired level of proficiency, availability of capital to fund future innovation, AXAM, AXAM Investments Inc., Axes, Axes America LLC, Axes America’s President and CEO, Axes Investment Management Co., Axes Securities, Axes Securities Co, bankrupt, BayBio, biggest long-term opportunity, Biomedical Access to Capital, biomedical cluster, biomedical company CEOs, Biomedical industry, biomedical innovation, biotechnology, British medical company Gyrus, burdensome and uncertain regulatory environment, business in financial transactions, California’s biomedical industry, Candidates in queue, Cayman Islands, CE Mark trial, CE Mark trial of the next-generation, CEO, CEO of ITX, challenging environment, CHI-California Healthcare Institute, choosing the right delivery method, clinical value, Collaborative partnership, commercialize medtech, Compete on price, Competitive landscape, competitive landscape is likely to change, Congress, considered as a first line therapy, constrained healthcare budgets, corporate finance, corporate partnerships as a source of financing, corporate venture capital as a finance source, Corporate venture funding, cost-effective solutions, Coverage and reimbursement issues, coverage and reimbursement issues are extremely important, critical decision factor, current global economic situation, cyclical problem of depressed macroeconomic conditions, dealing with high risk complications, declining procedure volume, delay a research or development project, Deliver value, deliver value to the overall healthcare system, delivered through two approaches, delivering better economic value, Demonstrate the economic value, demonstrate the economic value at both the provider and payer levels, Develop specific plans to accelerate global growth, develop specific plans to accelerate our global growth, devices approved for procedures, devices are priced at a hefty premium, Devices priced at hefty premium, diagnostics or medical equipment, Disease foundations, disease foundations/non-governmental organizations, dispute, Disruptive business model, disruptive business models, Diverse funding sources, dormant, Drexel, Drexel Burnham Lambert, Dynamic Dragons, each of the major emerging markets, economic downturn, Economic potential, economic potential of this specialized, emerging markets, engaging primarily with the physician, Enrollment in pilot study, enrollment in the pilot study, Europe, European Market, evaluated the merits of our products solely on the clinical value, Evaluated the merits of products, Evolving Market, Expanding insights into markets, expanding insights into these markets, FDA has the best regulatory approval process in the world, FDA regulatory approval process, Findings of the CEO Survey, FINRA records, first mover advantage, First-in-man, focus on emerging markets, force the players to increasingly compete on price, forced to look for other solutions, Forty-four percent of biomedical CEOs surveyed said they will look to licensing agreements, G.C. Venture Capital, Germany, Global Chef, Global Company, Global Company’s CEO Yokoo Nobumasa had also been CEO of Humalabo’s predecessor company L.E.M. Hanbai, global growth goals, global leadership position, Global Markets, global P&L responsibility, government grants, Growth opportunity, growth opportunity for our industry, Gyrus deal, Haio Fauser is a local market expert in each of the geographic regions, Hajime “Jim” Sagawa, Hajime Sagawa, Hamada Masayuki, Hayashi Masayuki, hide losses, high surgical risk, Hirata Kiichi, Humalabo, Ichimura Takuya, Implementation, Improve Execution, Improving ability to attract investment and grow, improving our ability to attract investment and grow, in the OUS market, In-country Opportunity Assessment, increased pressure in utilization, independent investigation from the company’s top institutional shareholders, informal capacity, Innovation, innovation and state-of-the-art medical technology, innovative technologies, Intellectual Property, IntelliSense Fine Force Technology, international business development experience, International Medical Consulting, Intraluminal, investigations from government, Investment firm, Investment Management, Investment of corporate funds into external endeavors, Investor Presentation, Investor Relations, issues being discussed throughout the biomedical industry by executives, J Alternative, J Bridge/Asia Alliance Holdings, Japan, Japanese camera maker Olympus, Japanese market, job creation, Joint Ventures, Kawada Hitoshi, Key Opinion Leader Connections, key opinion leader KOL, Kobe University in Economics, KOL Physicians, Kosaka Kiyoshi, Lack of funding, lack of innovation and productivity, laparoscopic vascular and endovascular capabilities, laparoscopic vascular and endovascular treatments, later stage corporations, leadership position, Leading biomedical region, less invasive treatment, licensing agreements, Look for other solutions, lower extremity arterial disease, Ltd., M&A deal, Maintain high standards of safety and effectiveness, maintain the high standards of safety and effectiveness, Major emerging markets, maker of microwavable plastic, many patients with age working against them, market in Europe, Marketing, Masayuki Hamada, massive decline in Olympus stock price, Matsumoto Kuniaki, MEDICA, Medical, Medical device, medical device industry, medical device innovation, Medical devices, medical devices companies, Medical technology, MedTech, meet the urgent need of patients, Meeting the needs, meeting the needs of the billions of people in emerging markets, Mergers & Acquisitions, Merrill Lynch, Michael Woodford, Minimal comparative clinical evidence, modality for abdominal aortic aneurysm repair, Mori Hisashi, multinational, Murata Masami, myriad of complications, mysterious payment, Nakagawa Akio, nascent technologies, necessity of the procedures to be performed in specialized centers, Neo Strategic Venture LP, New Investments Ltd., new medical devices, News Chef, Next-generation, NIOBE magnets, Nishihata Youhei, Nishimori Hitoshi, Nissho Iwai, Nobel Prize winning economist, Nomura, Nomura Securities, Non-governmental organizations NGO, noninvasive, obscure, Off-Shoring, Olympus Executive Vice President, onditions, Optimize Innovation, Optimize Innovation And Accelerate Globalization, OUS market, outside the US OUS, outside the USA, Outside The USA (OUS), Outside The USA (OUS) Global Markets Amid Soft US Sales, overt risk, Paine Webber, PaineWebber, paradigm-changing, partnerships, pharmaceuticals, physicians may have to perform 30 cases before they attain the desired level of proficiency, physicians’ learning curve, pivotal trial, Portfolio Management, preclinical evidence, preclinical studies, prevailing economic uncertainty, PricewaterhouseCoopers (PwC), principle investigator, Prioritize investment, Private Equity, Product Development, products in clinical development, progressive, project delays cited by private company CEOs, Proof-of-concept Lab Trials, proper selection of patients, prospective studies, Provider and payer levels, providing expertise. early clinical evidence, proximal aortic anastomosis, PwC, R&D, Raising money for a startup, recent launches, Recreate the ecosystem, recreate the ecosystem that has made the US the leading biomedical region, regulatory and reimbursement processes, Regulatory approval process in the world, regulatory changes, Regulatory Environment will Determine R&D Productivity, Regulatory framework based on consistency, regulatory framework that is based on consistency, reimbursement pressure, remote device manipulation system, remotely direct the catheter tip, renal aortic pathologies, representatives on their staff from each region, resources, restructuring initiatives, review our businesses, Robert Mundell, Robot-assisted intervention, Robot-assisted laparoscopic aortic procedures, robot-assisted laparoscopic aortic surgery, robotic computer-enhanced telemanipulation systems, robotic surgery, robotic technology, Robotically steerable endovascular catheter systems, robotics, Sagawa & Company, Sagawa Capital, Sagawa International Services, Sanyo Securities America, Sato Hideki, scheduled for completion, seeking diverse funding sources, serial entrepreneur, services to VC firms, shareholders, slower growth of US markets, snapshot of the biomedical industry in California, Sojitz, solutions that deliver better economic value, source of funding to the industry, special-purpose investment vehicles, splenic and renal artery aneurysm reconstruction, Stakeholders, Standard of care, start-up, state-of-the-art procedure, steerable catheter, Sterotaxis, Strategic Alliances, Strategic Planning, Strategy Development, strong and collaborative partnership between our business, surgical robotics, sustainable growth, Tactical Execution of Commercialization Programs, Takahashi Yoshinori, Tanabe Souhei/Shouhei, targeting a limited launch, tax incentives for innovation, Team work, Techno Mining Ltd., The CEO Survey, the current FDA regulatory approval process has slowed the growth, the current trajectory of rising healthcare costs is unsustainable, the future of global economic recovery, the investment of corporate funds into external endeavors, the standard of care, threats to the biomedical industry’s growth, To Improve Execution, top executive, Training of the physicians and staff, training of the physicians and staff is significant, two mysterious sets of corporate deals, UBS AG, Uncertain regulatory environment, Under development, unfavorable reimbursement decision from the CMS, Unsuitable for open surgery, unsuitable for this open surgery, Venture Capital, Wasserstein Perella & Co., we must prioritize our investment, widespread economic uncertainty, Widespread rollout, Working collaboratively, Working collaboratively with other stakeholders, www.axesim.co.jp, Yokoo Akinobu, Yokoo Nobumasa, Yoshida Minoru, Yoshikai Ryuzo
|
Comments Off